期刊文献+

磁珠分离结合质谱分析2型糖尿病肾病早期尿多肽谱

原文传递
导出
摘要 目的利用磁珠分离系统结合基质辅助激光解析电离飞行时间质谱(MALDI-TOF-MS)的方法获取糖尿病肾病(DN)早期的尿小分子差异多肽谱。方法按Mogensen标准,46例2型糖尿病患者经测3 d平均微量白蛋白尿排泄率(UAER)后分组,其中正常蛋白尿组(DM1)24例,微量白蛋白组(DM2)22例,健康对照组(C)20例。DM1及DM2组肾小球率过滤(GFR)均大于90 ml.min-1.1.73m-2。所有受试者留取空腹晨尿经采用弱阳离子(WCX)磁珠纯化试剂盒富集尿多肽,再采用MALDI-TOF-MS技术,获得尿液多肽谱,用ClinProtTM软件进行生物学比较分析。结果相对分子质量<12 000时,DM1组与C组相比,有15个蛋白质峰差异有统计学意义(均P<0.01)。DM2组与C组相比,有1个蛋白质峰差异有统计学意义(P<0.05)。DM1组与DM2组相比,有10个蛋白质峰差异有统计学意义(均P<0.01)。结论弱阳离子磁珠分离系统联合MALDI-TOF-MS蛋白质检测技术,能够获得健康人及DN早期尿液多肽谱,为进一步从中寻找早期诊断及评估药物干预效果需要的标志物提供前期的基础。
出处 《苏州大学学报(医学版)》 CAS 2012年第2期257-259,共3页 Suzhou University Journal of Medical Science
  • 相关文献

参考文献1

二级参考文献15

  • 1Y.-L. He,R. Sabo,J. Campestrini,Y. Wang,M. Ligueros-Saylan,K. C. Lasseter,S. C. Dilzer,D. Howard,W. P. Dole.The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin[J].European Journal of Clinical Pharmacology.2007(7)
  • 2V. Fonseca,A. Schweizer,D. Albrecht,M. A. Baron,I. Chang,S. Dejager.Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes[J].Diabetologia.2007(6)
  • 3N. Matikainen,S. M?ntt?ri,A. Schweizer,A. Ulvestad,D. Mills,B. E. Dunning,J. E. Foley,M.-R. Taskinen.Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes[J].Diabetologia.2006(9)
  • 4Catherine A. Abbott,Geoffrey W. McCaughan,Elizabeth Baker,Grant R. Sutherland.Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene[J].Immunogenetics.1994(5)
  • 5André Wettergren MD,Birgit Schjoldager MD,Poul Erik Mortensen MD,John Myhre MD,John Christiansen MD,Dr. Jens Juul Holst MD.Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man[J].Digestive Diseases and Sciences.1993(4)
  • 6Ahrén B,Simonsson E,Larsson H,Landin-Olsson M,Torgeirsson H,Jansson PA.Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes[].Diabetes Care.2002
  • 7Pratley RE,,Jauffret-Kamel S,Galbreath E,Holmes D.Twelveweek monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes[].Hormone and Metabolic Research.2006
  • 8Raz I,Chen Y,Wu M,Hussain S,Kaufman KD,Amatruda JM.Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes[].Current Medical Research and Opinion.2008
  • 9Lauster CD,McKaveney TP,Muench SV.Vildagliptin: a novel oral therapy for type 2 diabetes mellitus[].American Journal of Health System Pharmacy.2007
  • 10Choy M,Lam S.Sitagliptin: a novel drug for the treatment of type 2 diabetes[].Cardiology Review.2007

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部